Sentences with phrase «multiple clinical trials of»
She is an active clinical trialist, leading numerous multiple clinical trials of molecularly targeted agents for advanced cancer patients.
https://www.hopkinsmedicine.org/ Not exact matches
Speaking of checkpoint inhibitor drugs... Merck's star cancer immunotherapy treatment Keytruda is facing some troubling clinical trial incidents which have now compelled the Food and Drug Administration (FDA) to halt three studies of the drug in multiple myeloma, a rare blood cancer, after a number of patient deaths.
By printing multiple lung airways — or any other afflicted organ — from a human patient and testing drugs on them, pharma companies can bypass the ethically challenged practice of testing on animals and proceed to human clinical trials with greater confidence the drugs will actually work, according to Wadsworth.
Through talking to experts in the field over the past year, Gates said he had identified five areas of need: Understanding better how Alzheimer's unfolds, detecting and diagnosing it earlier, pursuing multiple approaches to trying to halt the disease, making it easier for people to take part in clinical trials of potential new medicines, and using data better.
A March 28, 2018, research note by JMP Securities analyst Michael King indicated that at the recent International Symposium on Amyloidosis in Japan, Alnylam Pharmaceuticals Inc. (ALNY: NASDAQ) reported multiple sets of results of clinical trials, separately evaluating its investigational RNA interference (RNAi) therapeutics patisiran and ALN - TTRsc02.
A couple of people talked about clinical trials (those that I talked about above), and Melissa (FAAN Teen Advisory Group member) talked about living with Multiple Food Allergies and other Auto - Immune Disorders.
A day after Collins was heard off the House floor discussing the possible sale of an Australian biotech stock, the company issued a news release further confirming its experimental treatment for multiple sclerosis had failed in clinical trials.
The value of Innate's shares tanked in late - June following a failed clinical trial for its multiple sclerosis treatment.
WASHINGTON — A day after Rep. Chris Collins was heard off the House floor discussing the possible sale of an Australian biotech stock, the company issued a news released further confirming its experimental treatment for multiple sclerosis had failed in clinical trials.
The value of stock in a multiple sclerosis drug company - which includes large holdings by members of Congress - collapsed Tuesday when company officials announced the drug failed during recent clinical trials.
«Every day, most of us take for granted that when we will to move, we can move any part of our body with precision and control in multiple directions and those with traumatic spinal cord injury or any other form of paralysis can not,» said Benjamin Walter, associate professor of Neurology at Case Western Reserve School of Medicine, Clinical PI of the Cleveland BrainGate2 trial and medical director of the Deep Brain Stimulation Program at UH Cleveland Medical Center.
Previously, Russo oversaw international clinical trials for Sativex, an oral spray made by GW Pharmaceuticals in Salisbury, U.K., that has been approved in 27 countries for treating spasticity caused by multiple sclerosis and in Canada for certain types of pain.
«The study results elucidate the molecular mechanisms underlying disease progression in multiple sclerosis models, providing a basis for future clinical trials to determine safety and efficacy of these chemical agents in humans with demyelinating disorders,» says Patrizia Casaccia, MD, PhD, Professor of Neuroscience, Genetics and Genomic Sciences at Mount Sinai and senior author of the study.
Researchers found that AcK1 closely resembles ShK, a peptide from a sea anemone, which has been shown to suppress autoimmune diseases and is currently in clinical trials for the treatment of multiple sclerosis.
In a trio of studies to be presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, investigators at Dana - Farber Cancer Institute will present the results of clinical trials showing that new drug combinations can significantly extend the time in which multiple myeloma is kept in check in patients with relapsed or treatment - resistant forms of the disease.
«There are multiple clinical trials going on right now with other members of the thiopeptide class.»
«These very important early clinical trials could provide hope for patients with all sorts of neurologic problems that involve paralysis such as stroke, brain injury, ALS and even multiple sclerosis.»
Watercress extract taken multiple times a day significantly inhibits the activation of a tobacco - derived carcinogen in cigarette smokers, researchers at the University of Pittsburgh Cancer Institute (UPCI), partner with UPMC CancerCenter, demonstrated in a phase II clinical trial presented today at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans.
For example, Matt Krause, director of human resources at CV Therapeutics, says, «Our research programs include multiple, cutting - edge cardiovascular product candidates in various stages of clinical trials and preclinical programs, all of which rely heavily on the contributions from our many B.S. - and M.S. - level scientists.»
It is critically important to understand how a genetic pathway actually functions and the consequences of interrupting it, especially in this case where there are multiple drug inhibitors of cyclin D being tested in clinical trials for breast cancer.
His work in designing anticancer compounds had led to millions of dollars in funding and multiple patents, as well as two compounds in clinical trials.
In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana - Farber Cancer Institute and other organizations report today online in the New England Journal of Medicine.
Results from a clinical trial investigating a new T cell receptor (TCR) therapy that uses a person's own immune system to recognize and destroy cancer cells demonstrated a clinical response in 80 percent of multiple myeloma patients with advanced disease after undergoing autologous stem cell transplants (ASCT).
«For the past five years, TAVR has been growing in use and acceptance largely based upon clinical evidence from multiple randomized controlled trials, but these have been limited to patients at the highest risk for surgery,» said Martin B. Leon, M.D., professor of medicine and director of the Center for Interventional Vascular Therapy at Columbia University Medical Center - New York Presbyterian Hospital and co-principal investigator of the PARTNER trials.
This clinical trial is the culmination of long - standing research led by Professor John Greenwood at the UCL Institute of Ophthalmology showing the potential therapeutic benefits of using statins to treat autoimmune diseases such as multiple sclerosis and uveitis.
The study is investigator led and has therefore focused on clinical need, targeting patients with progressive multiple sclerosis in whom most disability is incurred... The study also reports a predominant effect on neurodegenerative rather than inflammatory outcomes, suggesting a novel mechanism of action that might be suitable as combination treatment with immunomodulatory treatments... Further phase 3 studies to measure the effect of simvastatin on sustained disability, particularly in patients with non-relapsing secondary progressive and primary progressive multiple sclerosis, are clearly needed, but this trial represents a promising point from which to develop trials of progressive disease.»
However, the authors stress that «further clinical investigations will be essential to establish the optimal dose, duration and safety, and whether vitamin D2 or D3 have different effects on mortality risk, since the available trials are based on elderly populations in general (an age group with high competing risk of death often due to multiple co-existing disease conditions) and they do not typically include cause - specific deaths as the primary outcomes.»
«This study presents a novel strategy for treating multiple myeloma, and we hope to bring it to patients as part of a phase I clinical trial as soon as possible,» Hofmeister says.
Some multiple sclerosis patients may benefit if their immune system is selectively suppressed, according to the results of a small clinical trial performed at Harvard University.
BETs have been fast - tracked into clinical trials and have shown impressive slowing of tumor growth in multiple cancer types.
The Phase III clinical trial, conducted by the Radiation Therapy Oncology Group (RTOG), randomized 637 patients at multiple centers, including the University of Maryland Greenebaum Cancer Center, into two groups.
Described this week in the New England Journal of Medicine (July 4, 2013 print issue), the clinical trial was conducted at multiple sites in China and designed in partnership with a physician at UC San Francisco.
We have one of the most comprehensive CAR T cell programs in the world, with 14 CAR T clinical trials ongoing and plans to open numerous additional trials in the coming year, including for patients with multiple myeloma, prostate cancer, liver cancer and breast cancer.
When treatment begins to fail, University of Chicago medical oncologists with expertise in GIST can offer treatment with multiple novel agents, including sunitinib or investigational drugs available only through clinical trials.
The researchers noted that initial clinical trial data have been validated in larger phase II trials in the setting of relapsed / refractory HL, non-Hodgkin's lymphoma (NHL), and multiple myeloma (MM).
There are now multiple immunotherapies targeting clearance of alpha - synuclein from the brain in early - stage clinical trials, and multiple trials underway or in the works on the next generation of cell replacement therapies for dopaminergic neurons, including the TRANSEURO trial; the Summit4StemCell initiative, put together by Jeanne Loring — a researcher at The Scripps Research Institute who is exceptionally engaged with turning her research into therapies; a Japanese trial to be run by Jun Takahashi of Kyoto University in Japan (cf. here and here); and a trial centered at Memorial Sloan Kettering Cancer Center headed by cell biologist Lorenz Studer.
Methods: PD patients (n = 44) of a Phase I Multiple Ascending Dose clinical trial of PRX002 / RG7935 performed smartphone - based assessments for 24 weeks.
Therapies applying this paradigm to clear β - amyloid protein (Aβ) plaques and soluble aggregates from patients with Alzheimer's disease (AD) is an extremely active field of research, with multiple active and passive Aβ vaccines currently in human clinical trials.
One secondary outcome will be immunogenicity, meaning monitoring subjects for any emergence of antibodies against the infused therapeutic antibodies themselves; additionally, «Multiple clinical and exploratory biomarkers will be assessed» in the Phase Ib trial.
I am an investigator in multiple clinical trials, and I am a member of the breast, genitourinary, lung, and neuro - oncology multidisciplinary care teams at RWJ Somerset.
Researchers from Ruhr - University Bochum in Germany have reported that a drug currently in clinical trials for multiple sclerosis is neuroprotective in two mouse models of Huntington's disease.
Within monts, PRX002 became the subject of two randomized, double - blind, placebo - controlled clinical trials: a three - month single - dose trial (Phase Ia) and a six - month multiple - dose ascending trial (Phase Ib).
Gene and cell therapies have made important medical advances over the past three decade, developing technologies and testing novel therapies in multiple human clinical trials of many diseases.
Our group has 3 major goals: Develop novel therapeutic approaches based on centrosomal clustering To further develop our first prototype inhibitors of centrosomal clustering preclinically and to establish a robust and specific high throughput small molecule screen Discover key events in myeloma pathogenesis To investigate the pivotal transition from the pre-malignant, asymptomatic to malignant, symptomatic stages of plasma cell dyscrasias in order to understand the pathophysiology and thereby identify novel targets Translate small molecule therapeutics from bench to clinical trials To evaluate novel agents in the preclinical setting and to initiate early phase clinical trials in hematologic malignancies with focus on multiple myeloma
Dr. Katerina Akassoglou says a biomarker for multiple sclerosis could transform the diagnosis and care of MS, while also aiding in the development of new therapies and improving clinical trials.
«We explored the relationship between response to initial treatment and survival in patients with newly diagnosed multiple myeloma, based on data from 63 randomized clinical trials,» wrote researcher Maria Mainou, of the clinical research and evidence - based medicine unit at Aristotle University of Thessaloniki, Greece, and colleagues.
No Association Between Response Rates and Survival in Newly Diagnosed Multiple Myeloma: Results of a recent meta - regression analysis of 63 randomized clinical trials out of Greece concluded that there was no association between conventional response outcomes, such as complete response (CR) or very good partial response (VGPR), and overall (OS) or progression - free survival (PFS) in patients with newly diagnosed multiple myeloma in populations of patients who received stem cell transplant and those who Multiple Myeloma: Results of a recent meta - regression analysis of 63 randomized clinical trials out of Greece concluded that there was no association between conventional response outcomes, such as complete response (CR) or very good partial response (VGPR), and overall (OS) or progression - free survival (PFS) in patients with newly diagnosed multiple myeloma in populations of patients who received stem cell transplant and those who multiple myeloma in populations of patients who received stem cell transplant and those who did not.
Equally important, by securing access to the best drugs from multiple companies, CRI is able to conduct clinical trials of novel combinations that might not otherwise be conducted.
«A trial of this magnitude has many moving parts: multiple contracts and co-funders, a four - drug IND, a major industry partner, a biotech firm, and six university hospitals,» said Ramy Ibrahim, M.D., vice president of clinical development at the Parker Institute for Cancer Immunotherapy.
In addition, a growing number of immunotherapy clinical trials are in place to test this groundbreaking approach on other cancers like lymphoma, multiple myeloma, and for solid tumors, through trials in glioblastoma, mesothelioma, and ovarian and pancreatic cancer.